Atlas Trials

Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China

Clinical trial NCT03156985 · COMPLETED

Trial details

NCT number
NCT03156985
Sponsor
AstraZeneca
Status
COMPLETED
Study type
OBSERVATIONAL
Type 2 Diabetes Mellitus
Start date
2017-08-16
Primary completion
2021-01-27
Enrollment
3000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.